Beam Therapeutics
BEAMBeam Therapeutics is a biotechnology company developing a proprietary base editing platform to create precision genetic medicines for serious diseases.
Earnings
Next report
Nov 3, 2026 (Tomorrow)Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
Beam Therapeutics is a biotechnology company developing a proprietary base editing platform to create precision genetic medicines for serious diseases. Their technology enables single-base changes in the genome without causing double-stranded DNA breaks, potentially offering a safer and more precise alternative to traditional CRISPR nuclease editing. The company integrates gene editing, diverse delivery modalities like lipid nanoparticles, and internal manufacturing to advance a broad portfolio of curative therapies.
A pioneer in base editing technology with a fully integrated platform spanning discovery, delivery, and internal cGMP manufacturing.
FAQ
- What is Beam Therapeutics's market cap?
- Beam Therapeutics (BEAM) has a market capitalization of $3.0B and trades on NASDAQ.
- What is Beam Therapeutics's revenue and profitability?
- Beam Therapeutics generated $156.0M in trailing twelve-month revenue, representing a net margin of -742.4%, with free cash flow of -$372.8M. The latest reported period is Q2 2026.
- Who are Beam Therapeutics's competitors?
- Beam Therapeutics's key competitors include CRISPR Therapeutics, Intellia Therapeutics, Prime Medicine, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Beam Therapeutics partner with?
- Beam Therapeutics's notable partners include Pfizer Inc., Apellis Pharmaceuticals, Inc., Verve Therapeutics, Inc., and others.
- Where is Beam Therapeutics headquartered?
- Beam Therapeutics is headquartered in United States of America and employs approximately 436 people. It has been publicly traded since 2020.
